2021
DOI: 10.2174/17450179-v17-e211118-cpemh-2021-ht2-1910-12
|View full text |Cite
|
Sign up to set email alerts
|

The effects of Tyrosine Kinase Inhibitors (TKIs) in monotherapy and with add-on treatments on Health-related Quality of Life of People with Chronic Myeloid Leukemia: a systematic review of Randomized-Controlled Trials.

Abstract: Background: The era of establishing tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) changed the outcome and the course of this life-threatening malignancy. People suffering from CML have now a better prognosis and a longer life expectancy by the development of TKIs, even if it requires long term—often lifelong— treatments that are nonetheless associated with improved Health-related Quality of life (HRQoL). However, data on the effects of TKIs on HRQoL ar… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles